Nkarta, Inc. (NKTX)
2.70
0.00 (0.00%)
USD |
NASDAQ |
Mar 02, 16:00
2.61
-0.09
(-3.33%)
Pre-Market: 08:21
Nkarta Research and Development Expense (Annual) : 87.59M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Allogene Therapeutics, Inc. | 178.66M |
| ImmunityBio, Inc. | 216.56M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Agenus, Inc. | 155.53M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |